Day 1 Stream 1
The Role Biomarkers in Translational Science and Precision Medicine
Improving Cancer Patient Care Through Translational Science
Safety, efficacy and PK/PD biomarkers in drug development
Predictive biomarkers for drug development
Translating biomarkers from discovery stages through to exploratory clinical testing
Advancing Clinical Data and Precision Medicine
Big Data challenges in biomarker research

Day 1 Stream 2
Personalised Medicine, Companion Diagnostics & Patient Testing
Personalised healthcare: translating scientific innovation into patient benefit
The future of targeted therapy and precision medicine
Updates on companion diagnostics development
The impact of patient self-monitoring in healthcare
Challenges of drug & diagnostics co-development

Day 1 Stream 3
Biomarker: Clinical Development & Clinical Trials
Overcoming challenges of clinical validation & translation
Surrogate endpoints: utilising biomarkers in clinical trials
Implementing clinical biomarker in Auto-Immune Diseases
Transforming clinical development through biomarker driven clinical trials design
Predictive biomarker discovery in proof – of concept clinical

Day 2 Stream 1
Biomarker Discovery and Development
Biomarker assay development and validation
Novel biomarker discovery & identification
Discovery and Development of neurological and immune-oncology disease markers, Rare Diseases, Organ and Cardiovascular diseases
Predictive cancer biomarkers for targeting therapy
New advances in biomarker technologies and platform
Imaging and Cytometry Technologies

Day 2 Stream 2
Clinical Diagnostics, NGS & Genomic Marker Development
NGS for clinical testing & diagnostics
Case Studies: microRNA’s, CTCs, circulating free DNA & exosomes
Biomarkers for non-invasive diagnosis
The importance of liquid biopsies
Clinical effectiveness of diagnostic markers & screening of new markers

Day 2 Stream 3
Clinical Diagnostics, NGS & Genomic Marker Development
NGS for clinical testing & diagnostics
Case Studies: microRNA’s, CTCs, circulating free DNA & exosomes
Biomarkers for non-invasive diagnosis
The importance of liquid biopsies
Clinical effectiveness of diagnostic markers & screening of new markers

Benefits to Attending
- Hear from and meet with the key innovators in biomarker research from Merck, AstraZeneca, Genentech, Pfizer, Bristol Myers Squibb, Takeda, Bayer and c-Path, NIH, Translational Genomics Institute
- Discover novel pre-clinical and clinical biomarker research strategies in therapeutic areas including: Oncology, COPD, Immune-oncology, Autoimmune Diseases, Cardiovascular, Fibrotic Disorders
- Discover successful case studies on the application of Biomarker research in Clinical Development & Clinical Trials Design and Management
- Learn about approaches of Biomarkers research in Precision Medicine, Personalised Healthcare & Companion Diagnostics Development
- Advance your understanding in the recent developments in Integrative Biology, Clinical Diagnostics and NGS & Genomic Markers, and deployment in the clinic.
- Advancing Precision Medicine in managing clinical data and managing biomarker data
- A high quality programme devised with the help of our esteemed advisory board. Presentations will cover areas including drug design, discovery informatics and discovery data, computational chemistry, open innovation and external research strategies
- Co-located with our Drug Discovery USA Congress

Meet Senior Decision Makers
Over 180 VPs, Directors & Senior Managers from leading pharmaceutical organisations, biotech companies and academic institutions will attend the event. Delegate job titles include:

- Biomarker Discovery
- Biomarker Validation
- Companion Diagnostics
- Clinical & Genomic Biomarkers
- Imaging Technologies
- Personalised Medicine
- Preclinical Safety
- Translational Medicine

Discover New Solutions
Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Services to be discussed include:

- Assay Validation
- Biomarker Verification
- Biomarker Data Management
- Diagnostic Development
- Patient Selection Markers
- Regulatory Services
- Genomic Biomarkers
- Clinical Validation

For booking details & registration fees please refer to the last page or visit: [http://www.biomarkersusa-congress.com/marketing](http://www.biomarkersusa-congress.com/marketing)
2016 Confirmed and Reserved Biomarkers USA Congress Speakers include:

- Jianda Yuan, Director, Translational Research Group, Merck Research Laboratories
- Jean-François Martini, Senior Director, Immuno-oncology, Early Development and Translational Oncology, Global Product Development-Oncology, Pfizer
- John Michael Sauer, PSTC Executive Director, c-PATH PSTC
- Mark E. Curran, Vice President, Immunology, Systems Pharmacology & Biomarkers, Janssen Research & Development
- Ann Kapoun, Vice President, Translational Medicine, OncoMed Pharmaceuticals Inc
- J. Carl Barrett, Vice President of Translational Science, Oncology Innovative Medicines Division, AstraZeneca Pharmaceuticals
- Philip M. Arlen, President & Chief Executive Officer, Precision Biologics
- Johan Luthman, VP Neuroscience R&D, Franchise Integrator, Eisai
- Mark Day, Executive Director and Head of External Research and Scouting, Alexion Pharmaceuticals
- Zhenhao Qi, Associate Director, Clinical Genetics and Genomics, Clinical Translational Technologies and Operation, ECTR, Bristol Myers Squibb
- Arijit Chakravarty, Director, Modelling and Simulation, Takeda Pharmaceuticals
- Frank Kramer, Director Biomarker Expert – Cardiovascular Diseases, Clinical Sciences - Experimental Medicine CV/HEM, Bayer
- Chan Whiting, Associate Director, Aduro Biotech
- Michael A. Kiebish, Chief Precision Medicine Officer, BERG Pharma
- David L. Boyle, Professor of Medicine, Director, Biomarker Laboratory, Director, Translational Technology Division, ACTRI
- Geoffrey M. Kuesters, Senior Scientist, Merrimack
- Jean-Marie Bruey, Companion Diagnostics Group Leader, Genentech
- Robert Pierce, Chief Scientific Strategist, OncoSec Medical
- Richard Baumgartner, Senior Principal Scientist, Biostatistics, Merck
- Anka G. Ehrhardt, Director Clinical Cytometry, Biomarker Technologies, ECTR, Bristol-Myers Squibb Co
- Nikolai Ivanov, Manager, Research Technologies, Philip Morris International R&D
- David Roberts, Head of Project Management, Assay Research Lab, NIBR Oncology, Novartis Institutes for BioMedical Research
- Zoë Johnson, Section Head, Bioanalytical Sciences, Exploratory Science & Translational Medicine (ESTM), Novimmune SA
- Eric Kowack, Vice President, Program Team Leader, Ignyta Inc
- Anand Giddabasappa, Principal Scientist, Global Science and Technology, Pfizer
- Nathan Hedrick, Principle Scientist Clinical Cytometry, CTTO, ECTR, Bristol-Myers Squibb Co
- David M Jackson, VP - Diagnostic / Companion Diagnostics, Arno Therapeutics, Inc
- Oliver Kretz, Head of Protein Analytics, University of Tuebingen
- Stephen Pennington, Professor of Proteomics, University College Dublin & Atturos
- Murtaza Mehdi, Director, Corporate and Business Development, Foundation Medicine
- John Beeler, VP of Business Development, Inivata
- Subrata Sen, Professor and Deputy Chair, Department of Translational Molecular Pathology, The University of Texas M.D. Anderson Cancer Center
- Adil Daud, Professor of Medicine, University of California, San Francisco
- Bodour Salhia, Assistant Professor, University of Southern California
- Marina Sirota, Assistant Professor, University of California, San Francisco
- Kevin Knopf, Medical Director, Cancer Commons

If you’re on Twitter, make sure to follow us @BMD_Congress and join the Congress conversation on #BIOM16

2016 Sponsors include:
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.30 – 08.20</td>
<td>Registration – Cortez Prefunction</td>
</tr>
<tr>
<td>08.20 – 08.25</td>
<td>Oxford Global’s Welcome Address – Cortez 3</td>
</tr>
<tr>
<td>08.25 – 08.30</td>
<td>Chairperson’s Opening Address</td>
</tr>
<tr>
<td></td>
<td>Stream Chair: Daniel Chelsky, Chief Scientific Officer, Caprion</td>
</tr>
<tr>
<td>08.30 – 09.00</td>
<td>Keynote Address</td>
</tr>
<tr>
<td></td>
<td>Next Generation Biomarkers For The Era Of Combination Cancer Immunotherapy</td>
</tr>
<tr>
<td></td>
<td>• First- and second-generation biomarkers that predict response to PD-1-directed monotherapy</td>
</tr>
<tr>
<td></td>
<td>• Biomarker challenges in an era with an enhanced cancer immunotherapy armamentarium</td>
</tr>
<tr>
<td></td>
<td>• Precision medicine in cancer immunotherapy</td>
</tr>
<tr>
<td></td>
<td>Jianda Yuan, Director, Translational Research Group, Merck Research Laboratories</td>
</tr>
<tr>
<td>09.00 – 09.30</td>
<td>Improving Patient Care Through Translational Science</td>
</tr>
<tr>
<td></td>
<td>• Biomarkers- improving the probability of success</td>
</tr>
<tr>
<td></td>
<td>• The utility of Biomarkers for rare diseases</td>
</tr>
<tr>
<td></td>
<td>• FDA updates on Orphan and rare diseases</td>
</tr>
<tr>
<td></td>
<td>Mark Day, Executive Director and Head of External Research and Scouting, Alexion Pharmaceuticals</td>
</tr>
<tr>
<td>09.30 – 10.00</td>
<td>Solution Provider Presentation</td>
</tr>
<tr>
<td></td>
<td>Daniel Chelsky, Chief Scientific Officer, Caprion</td>
</tr>
<tr>
<td>10.00 – 11.20</td>
<td>Coffee &amp; Refreshments, One to One Meetings x4, Poster Presentation Sessions</td>
</tr>
<tr>
<td>11.20 – 11.50</td>
<td>Development of Preclinical Models and Translation in the Clinic</td>
</tr>
<tr>
<td></td>
<td>• Strategies in diagnostics development</td>
</tr>
<tr>
<td></td>
<td>• Presenting early clinical data</td>
</tr>
<tr>
<td></td>
<td>Ann Kapoun, Vice President, Translational Medicine, OncoMed Pharmaceuticals Inc</td>
</tr>
<tr>
<td></td>
<td>Challenges of Drug and Diagnostic Co-Development: Examples in Auto-Immune Disorders</td>
</tr>
<tr>
<td></td>
<td>• Precision Medicine remains a critical unmet need in auto-immune disorders</td>
</tr>
<tr>
<td></td>
<td>• Progress toward prognosis and prediction in RA and IBD</td>
</tr>
<tr>
<td></td>
<td>• Importance of genetic factors in drug response – learnings from genome sequencing in RA</td>
</tr>
<tr>
<td></td>
<td>• Role of disease phenotypes in companion diagnostic development</td>
</tr>
<tr>
<td></td>
<td>Mark E. Curran, Vice President Systems Pharmacology and Biomarkers, Janssen R&amp;D</td>
</tr>
</tbody>
</table>

For more information please contact marketing@oxfordglobal.co.uk
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.50 – 12.20</td>
<td><strong>Translational Sciences In Oncology: From The Bench To The Clinic And Back Again</strong></td>
</tr>
<tr>
<td></td>
<td>• Precision Medicine and Companion Diagnostics</td>
</tr>
<tr>
<td></td>
<td>• Development of PARP and EGFR inhibitors</td>
</tr>
<tr>
<td></td>
<td>• NGS and ctDNA</td>
</tr>
<tr>
<td></td>
<td>J. Carl Barrett, Vice President of Translational Science, Oncology Innovation Medicines Division, AstraZeneca Pharmaceuticals</td>
</tr>
<tr>
<td></td>
<td><strong>Paving the Roads For Discoveries: Clinical Biomarkers At The Intersection Between Science and Logistics</strong></td>
</tr>
<tr>
<td></td>
<td>• The importance of top quality in balance with the need for speed in clinical studies</td>
</tr>
<tr>
<td></td>
<td>• The impact of logistics on science and innovation in clinical studies, and ways to use collaboration to overcome these challenges and deliver valuable biomarker data</td>
</tr>
<tr>
<td></td>
<td>Anka G. Ehrhardt, Director Clinical Cytometry, Biomarker Technologies, ECTR, Bristol-Myers Squibb Co</td>
</tr>
<tr>
<td>12.20 – 12.50</td>
<td><strong>A Novel Strategic Approach to Conducting Dx-Driven Oncology Trials Drives Enrollment in Rare Patient Populations</strong></td>
</tr>
<tr>
<td></td>
<td>Eric Kowack, Vice President, Program Team Leader, Ignyta Inc</td>
</tr>
<tr>
<td>12.50 – 13.50</td>
<td>Lunch and One to One Meetings x2</td>
</tr>
<tr>
<td></td>
<td><strong>Innovative Use of PK/PD In The Development Of A Biologic Drug For A Rare Pediatric Disease</strong></td>
</tr>
<tr>
<td></td>
<td>• Based on the growing evidence that IFNγ plays a pivotal role in HLH, NI-0501, an anti-IFNγ monoclonal antibody, is being developed as the first targeted treatment of HLH.</td>
</tr>
<tr>
<td></td>
<td>• On the basis of calculated neutralizing NI-0501 concentrations, NI-0501 PK parameters in healthy volunteers and PK information from use of recombinant IFNγ in humans, we predicted, by means of PK modelling and simulation, the dose needed to neutralize existing and de novo IFNγ production.</td>
</tr>
<tr>
<td></td>
<td>• IFNγ neutralization in serum following NI-0501 infusion was confirmed through down-modulation of IFNγ-inducible proteins, such as CXCL9 and CXCL10.</td>
</tr>
<tr>
<td></td>
<td>Zoë Johnson, Section Head, Bioanalytical Sciences, Exploratory Science &amp; Translational Medicine (ESTM), Novimmune SA</td>
</tr>
<tr>
<td>13.50 – 14.20</td>
<td><strong>The Case Study – Clinical Studies in COPD and Cardiovascular therapeutic areas and the Role of Biomarkers</strong></td>
</tr>
<tr>
<td></td>
<td>• Biomarkers of exposure measured in pre-clinical and clinical studies</td>
</tr>
<tr>
<td></td>
<td>• Biomarkers of disease risk, COPD and CVD endpoints</td>
</tr>
<tr>
<td></td>
<td>Nikolai Ivanov, Manager, Research Technologies, Philip Morris International R&amp;D</td>
</tr>
</tbody>
</table>

For more information please contact marketing@oxfordglobal.co.uk
14.20 – 14.50 | Population Medicine: Selection of Phase II Indications Based on Patient Biology

- Prior to initiating Phase II trials, performing comprehensive assessment of molecular presentation of patient populations responding/not responding to 1st or 2nd line therapy.
- Defining populations for rapid progression/metastasis as well as long term survival
- An example will be given for BERG’s BPM 31510 clinical trial development as well as selection of indications based on OMICS signatures

Michael A. Kiebish, Chief Precision Medicine Officer, BERG Pharma

14.50 – 15.20 | Affimer® Binders As Alternatives To Antibodies For Biomarker Detection

- Biomarker assays frequently rely on antibodies
- The availability of antibodies with requisite specificity and affinity can be rate-limiting
- Affimer® technology offers an alternative, more rapid route to the production of specific, high affinity binders
- This presentation will focus on internal projects where high quality Affimer® binders have been developed and applied in assay development

Paul Ko Ferrigno, Director, External Collaborations, Avacta

15.20 – 15.50 | Precision Medicine in the Community Oncology Clinic

- Real time application of precision medicine in actively treated cancer patients
- Challenges in dissemination of genomic knowledge and next generation sequencing in real time
- Economic challenges and opportunity in precision oncology

Kevin Knopf, Medical Director, Cancer Commons

15.50 – 16.30 | Afternoon Refreshments, One to One Meetings x2, Poster Presentation Sessions

Cortez Ballroom

16.30 – 17.00 | Integrating Clinical and Omic Data To Advance Precision Medicine

- How to leverage publicly available data for research
- Biomarker and therapeutic discovery integrating clinical and omic data
- Drug discovery in the era of precision medicine

Marina Sirota, Assistant Professor, University of California, San Francisco

For more information please contact marketing@oxfordglobal.co.uk
**Biomarkers and Precision Medicine USA Congress**

**Day 1 – 3rd October 2016**

<table>
<thead>
<tr>
<th>17.00 – 17.30</th>
<th>Turning Data Into Information Into Knowledge – Current Challenges With Biomarker Data</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Utilization of Genomic data for clinical trial design</td>
</tr>
<tr>
<td></td>
<td>Utilization of a broad NGS platform for enrollment acceleration of targeted clinical trials</td>
</tr>
<tr>
<td></td>
<td>Associated Time and Cost savings to the therapeutic program</td>
</tr>
<tr>
<td></td>
<td><strong>JOINT PRESENTATION:</strong></td>
</tr>
<tr>
<td></td>
<td>David Roberts, Head of Project Management, Assay Research Lab, NIBR Oncology, Novartis Institutes for BioMedical Research</td>
</tr>
<tr>
<td></td>
<td>Murtaza Mehdi, Director, Corporate and Business Development, Foundation Medicine</td>
</tr>
</tbody>
</table>

**Companion Diagnostic and Clinical Assay Development and Implementation**

<table>
<thead>
<tr>
<th>17.30–18.00</th>
<th>Healthy Donor Studies And The Importance Of A Reference Cohort For Establishing Personalized Biomarker Strategies</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>Case Study: Development And IDE Approval Of A Companion Diagnostic</strong></td>
</tr>
<tr>
<td></td>
<td>• Strategic planning</td>
</tr>
<tr>
<td></td>
<td>• Partnering</td>
</tr>
<tr>
<td></td>
<td>• Co-development program</td>
</tr>
<tr>
<td></td>
<td>• Regulatory interactions</td>
</tr>
<tr>
<td></td>
<td><strong>David M Jackson, VP - Diagnostic / Companion Diagnostics, Arno Therapeutics, Inc</strong></td>
</tr>
</tbody>
</table>

18.00 Networking Drinks and End of Day One

Cortez Ballroom

---

**Biomarkers and Precision Medicine USA Congress**

**Day 2 – 4th October 2016**

<table>
<thead>
<tr>
<th>07.50 – 08.00</th>
<th>Registration – Cortez Prefunction</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Stream Chair: Senior Representative, Axio</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>08.00 – 08.30</th>
<th>Stream Keynote Address: Developments in Neuroscience and Translational Medicine</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Johan Luthman, VP Neuroscience R&amp;D, Franchise Integrator, Eisai</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>08.30 – 09.00</th>
<th>Critical Path Institute’s Predictive Safety Testing Consortium – The Road to Translational Safety Biomarker</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• This presentation will describe in detail the current approach accepted by the FDA, EMA, and PMDA for the qualification of translational safety biomarkers for use in nonclinical species and humans.</td>
</tr>
<tr>
<td></td>
<td>• Several illustrative examples will also be discussed from both their biological and regulatory science prospective.</td>
</tr>
<tr>
<td></td>
<td>• The objective of the presentation will be to highlight the importance of safety biomarkers in drug development and the value of biomarker qualification</td>
</tr>
<tr>
<td></td>
<td><strong>John Michael Sauer, PSTC Executive Director, c-PATH PSTC</strong></td>
</tr>
</tbody>
</table>

Conference Room: Cortez 3

**Day 2 Stream 1: Biomarker Discovery and Development – Qualification, Validation, Assay Development, Imaging in Different Therapeutic Approaches**

Stream Chair: Senior Representative, Axio

---

Conference Room: Hillcrest 2

**Day 2 Stream 2: Innovative Biology - Clinical Diagnostics, NGS & Genomic Marker Development**

Stream Chair: Senior Representative, Fios Genomics

For more information please contact marketing@oxfordglobal.co.uk
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Details</th>
</tr>
</thead>
</table>
| 09.00 – 09.30 | The SAFE-T Consortium - Drug Induced Organ Injury Biomarker Across the Species Barrier  
- Mass spectrometry-based immunoassays for animal models  
- Drug-induced kidney injury marker in monkey, dog and men  
- Drug-induced liver injury marker in monkey, dog and men  
Oliver Poetz, Head of Protein Analytics, Natural and Medical Sciences Institute, University of Tuebingen | Managing the Cancer Genome Atlas and Implications on Biomarker Discovery and Development  
RESERVED: Jean C. ZenKlusen, Director, The Cancer Genome Atlas, Center for Cancer Genomics, Office of the Director, National Cancer Institute, National Institutes of Health |
| 09.30 – 10.00 | Biomarker Strategy Supporting The Development of ARGX-110  
- CD70 is an attractive target for the treatment of oncology and autoimmune diseases  
- ARGX-110 is an engineered, differentiated antibody targeting CD70, currently in Phase I/II clinical trials  
Luc Van Rompaey, VP Translational Medicine, Argenx BVBA | The Use of cfDNA (“Liquid Biopsy”) In Clinical Trials for Novel Agents  
- Collection of tumor tissue biopsy in the recurrent/metastatic setting can be challenging due to accessibility of biopsiable site, potential risk for patient’s safety and also cost.  
- Circulating free (tumor) DNA (cfDNA) is blood based biospecimen that is a reliable yet less invasive source of tumor DNA (and/or RNA).  
- We will review 2 examples of mutation detection in plasma in Breast Cancer (ESR1 mutations) and Lung Cancer (ALK/ROS1 mutations), and discuss advantages and pitfalls of currently available platforms.  
Jean-François Martini, Senior Director, Immuno-oncology, Early Development and Translational Oncology, Global Product Development-Oncology, Pfizer |
| 10.00 – 11.00 | Morning Coffee, One to One Meetings x3, Poster Presentation Sessions  
Cortez Ballroom  
Conference Room: Cortez 3  
Day 2 Stream 1: Biomarker Discovery and Development – Qualification, Validation, Assay Development, Imaging in Different Therapeutic Approaches | Day 2 Stream 2: Clinical Diagnostics, NGS & Genomic Marker Development  
Conference Room: Hillcrest 2 |
| 11.00 – 11.30 | Solution Provider Presentation  
Matthias Scheffler ,Chief Business Officer – Head of Marketing & Sales, Biocrates | Solution Provider Presentation  
For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk |
| 11.30 – 12.00 | Solution Provider Presentation  
For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk | Solution Provider Presentation  
For sponsorship opportunities please contact sponsorship@oxfordglobal.co.uk |
| 12.00 – 12.30 | Imaging (In vivo) in Pre-clinical Discovery and Development  
Molecular Imaging has been a great tool in clinical oncology and oncology drug discovery/development. Imaging has been a good tool in diagnosis, evaluation of predictive and prognostic biomarkers and determining of therapeutic benefit of a drug. In this presentation we will discuss various imaging modalities with examples from pre-clinical oncology drug discovery.  
Anand Giddabasappa, Principal Scientist - GS & T - Comparative Medicine, Pfizer | Precision of Circulating Tumor DNA (ctDNA) Analysis in Oncology  
- In the absence of an invasive tissue biopsy, ctDNA can be used as a ‘liquid biopsy’ for molecular profiling of actionable genetic alterations in cancer patients.  
- Many of the mutations present in ctDNA exist at low allele fractions that would be routinely missed using less sensitive assays thus reinforcing the importance of using a high sensitivity assay for ctDNA analysis.  
- This presentation will focus on the clinical application of InVision™, a robust and reproducible platform exhibiting high sensitivity and specificity for the detection of genomic alterations in ctDNA.  
John Beeler, VP of Business Development, Inivata |
### Biomarkers and Precision Medicine USA Congress
#### Day 2 – 4th October 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Stream Chair: Senior Representative, Axio</th>
<th>Stream Chair: Senior Representative, Fios Genomics</th>
</tr>
</thead>
</table>
| 12.30 – 13.30 | Lunch & One to One Meetings x3  
Cortez Ballroom                                                      |                                                                                                           | From Innovation Pilot to Clinical Trials: Which Technologies Deliver Reliable Gene Expression in Clinical FFPE samples? |
|            | Stream Chair: Senior Representative, Axio                                                                 |                                                                                                           | Highiy fragmented RNA in FFPE presents a significant challenge for reliably detecting gene expression using traditional TaqMan qPCR |
| 13.30 – 14.00 | Biomarkers In Proof of Concept Trials In Rheumatoid Arthritis       | David L. Boyle, Professor of Medicine, Director, Biomarker Laboratory.  
Director, Translational Technology Division, ACTRI                                                                 | We tested four new technologies to determine which platform will improve gene expression in CRC archival FFPE, thus enable accurate gene expression analysis of FFPE samples in clinical programs and alignment of best method to future diagnostic development |
| 13.00 – 13.30 | Biomarkers In Proof of Concept Trials In Rheumatoid Arthritis       | David L. Boyle, Professor of Medicine, Director, Biomarker Laboratory.  
Director, Translational Technology Division, ACTRI                                                                 | We tested four new technologies to determine which platform will improve gene expression in CRC archival FFPE, thus enable accurate gene expression analysis of FFPE samples in clinical programs and alignment of best method to future diagnostic development |
| 13.30 – 14.00 | Biomarkers In Proof of Concept Trials In Rheumatoid Arthritis       | David L. Boyle, Professor of Medicine, Director, Biomarker Laboratory.  
Director, Translational Technology Division, ACTRI                                                                 | We tested four new technologies to determine which platform will improve gene expression in CRC archival FFPE, thus enable accurate gene expression analysis of FFPE samples in clinical programs and alignment of best method to future diagnostic development |
| 14.00 – 14.30 | Biomarker Development for Intratumoral Gene Therapy with DNA-encoded IL-12 | Robert Pierce, Chief Scientific Strategist, OncoSec Medical                                                                 | Deregulated MicroRNAs as Cancer Biomarkers                                                                 |
| 14.00 – 14.30 | Biomarker Development for Intratumoral Gene Therapy with DNA-encoded IL-12 | Robert Pierce, Chief Scientific Strategist, OncoSec Medical                                                                 | Deregulated MicroRNAs as Cancer Biomarkers                                                                 |
| 14.30 – 15.00 | Biomarker Assay Development in Immunology  
Nathan Hedrick, Principle Scientist Clinical Cytometry, CTTO, ECTR, Bristol-Myers Squibb Co | Conference Room: Cortez 3  
Day 2 Stream 1 : Biomarker Discovery and Development – Qualification, Validation, Assay Development and Imaging in Different Therapeutic Areas | Conference Room: Hillcrest 2  
Day 2 Stream 2: Clinical Diagnostics, NGS & Genomic Marker Development |
| 14.30 – 15.00 | Biomarker Assay Development in Immunology  
Nathan Hedrick, Principle Scientist Clinical Cytometry, CTTO, ECTR, Bristol-Myers Squibb Co | Conference Room: Cortez 3  
Day 2 Stream 1 : Biomarker Discovery and Development – Qualification, Validation, Assay Development and Imaging in Different Therapeutic Areas | Conference Room: Hillcrest 2  
Day 2 Stream 2: Clinical Diagnostics, NGS & Genomic Marker Development |
| 15.00 – 15.30 | Afternoon Refreshments & One to One Meetings x2  
Cortez Ballroom                                                      |                                                                                                           | Role of Biomarker in Genomic Medicine - Identification of Predictive DNA Methylation Biomarkers  
• feasibility of DNA methylation liquid biomarkers  
• the need for biomarkers to prognosticate/predict breast cancer recurrence |
| 15.00 – 15.30 | Afternoon Refreshments & One to One Meetings x2  
Cortez Ballroom                                                      |                                                                                                           | Role of Biomarker in Genomic Medicine - Identification of Predictive DNA Methylation Biomarkers  
• feasibility of DNA methylation liquid biomarkers  
• the need for biomarkers to prognosticate/predict breast cancer recurrence |
| 15.30 – 16.00 | Panel Discussion- Immuno-oncology Biomarker Development  
Challenges in Precision medicine  
Status of PDL1 assay and biomarker development and other pathways  
Non Respondence of PDL1  
Lessons learnt  
Chair: Adil Daud, Professor of Medicine, University of California, San Francisco  
Panellists:  
Robert Pierce, Chief Scientific Strategist, OncoSec Medical  
Chan Whiting, Associate Director, Aduro Biotech | Delegates are welcome to attend the co-located presentations | Delegates are welcome to attend the co-located presentations |

For more information please contact marketing@oxfordglobal.co.uk
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter</th>
<th>Speaker Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00 – 16.30</td>
<td>Biomarker Strategy To Guide Clinical Development Of Cancer Immunotherapy</td>
<td>Adil Daud, Professor of Medicine, University of California, San Francisco</td>
<td>Delegates are welcome to attend the co-located presentations</td>
</tr>
<tr>
<td></td>
<td>• Review novel Biomarkers</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discuss clinical and Biomarkers correlations</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Mutation burden and response</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.30 – 17.00</td>
<td>Cancer Immunotherapy Using Live-Attenuated <em>Listeria monocytogenes</em>: Biomarker Perspective</td>
<td>Chan Whiting, Associate Director, Aduro Biotech</td>
<td>Delegates are welcome to attend the co-located presentations</td>
</tr>
<tr>
<td></td>
<td>• Overview of Aduro’s core LADD platform (Live, Attenuated, Double-Deleted <em>Listeria monocytogenes</em>)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Clinical trial updates in pancreatic cancer and mesothelioma</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Ongoing analyses in tumor infiltrating immune cells, circulating cellular, tumor/protein biomarkers that may account for differential patient responses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.00 – 17.30</td>
<td>The Signal Is The Noise: Heterogeneity As A Biomarker of Treatment Response</td>
<td>Arijit Chakravarty, Director, Modeling and Simulation, Takeda Pharmaceuticals Int. Co., Cambridge (US)</td>
<td>Delegates are welcome to attend the co-located presentations</td>
</tr>
<tr>
<td></td>
<td>• The evolutionary view of cancer and why it changes things</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Heterogeneity as the raw material of evolution</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Applying evolutionary theory in a practical drug development setting</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.30</td>
<td>End of Conference</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Delegate Details

Please complete fully and clearly. Please photocopy for additional delegates.

Title: _________________________ Forename: _________________________ Surname: _________________________

Job Title: _________________________

Company/Organisation: _________________________

Email: _________________________

Address: _________________________

Postcode: _________________________

Country: _________________________

Direct Telephone: _________________________ Direct Fax: _________________________

Mobile: _________________________ Switchboard: _________________________

Signature: _________________________

Date: _________________________

Agreed Terms between the Organiser (Oxford Global Marketing Ltd) and the Delegate.

Delegate Booking Fee

The Delegate Booking Fee includes: lunches and refreshments throughout the Congress event, conference presentations, workshop and panel sessions, scheduled one-to-one meetings and networking/social events, conference and speaker notes. Delegates may attend, free of charge, all sessions arranged by the Organiser. An admin surcharge of £50 / $75 will be applied to payments settled following the receipt of an invoice. This charge will not be applied to payments settled online.

Vendor Delegates will not be eligible for one to one meetings unless they purchase a sponsorship meetings package. These can only be purchased directly from Oxford Global Marketing Ltd and not via the online booking facility.

Poster Presentations

Those who have booked a poster presentation at the event must provide the poster title, abstract (200 words or less), principal author, organisation, mailing address, email, telephone, fax and additional authors, within a month of registration. All poster spaces will be for A0 (841mm x 1189mm) portrait size.

Cancellation and Curtailment

Delegates and vendor delegates are subject to the following charges and refunds upon withdrawal or cancellation.

More than 6 months prior 35% cancellation fee / 65% refund

Between 6 and 3 months prior 75% cancellation fee / 25% refund

Less than 3 months prior Full cancellation fee / No refund

Data Protection

The data controller is the Organiser. The Organiser may disclose such personal information to Registered Event Sellers (Solution Providers) and other Delegates but solely for the purposes of the Event. The Delegate consents to the use of his/ her personal and company information on the terms set out herein.

Miscellaneous

This Agreement may not be transferred or assigned by either the Delegate or the Delegate’s Company. If for any reason the Organiser has to cancel or postpone this Event, the Organiser reserves the right to transfer this Booking to another Congress within the same sector to be held within twelve months. Should another Congress in the same sector not be available within this period, the Booking Fee will be refunded.

I agree to the above Terms and Conditions

Registration Fees

I would like to attend: (Please tick as appropriate)

Industry Delegates (Biopharma, Pharma or Biotech Companies)

- Congress £840 / $1,090
- Day 1 £520 / $680
- Day 2

Academic Delegates

- Congress £520 / $680
- Day 1 £310 / $420
- Day 2

Vendor Delegates (CROs, Consultants, Technology and Service Providers)

- Congress Only £1,350 / $1,750
- Day 1 £380 / $1,080
- Day 2

- Poster Presentation £250 / $345

PROMOTIONAL LITERATURE DISTRIBUTION

- Distribution of your company’s promotional literature to all conference attendees £999 / $1,300

Documentation

I cannot attend but would like to purchase access to the following:

- Access to the online conference presentations £499 / $660
- Conference presentations - paper copy £499 / $660

How to Pay (choose one of the following payment options)

Number of delegates:

- Industry del(s) ________
- Academic del(s) ________
- Vendor del(s) ________

Special Offer: 3 for 2

Offer is only valid on the congress and for those registering at Industry or Academic rates

- CREDIT CARD: □ Visa □ MasterCard □ Maestro □ Amex

Credit Card Number: _________________________

Valid from: / Expiry Date: / Security code: _________________________

Cardholders name: _________________________

Signature: _________________________ Date: _________________________

I agree to the above Terms and Conditions

If you have any further queries please call the marketing team on +44(0)1865 248455 or email marketing@oxfordglobal.co.uk